[go: up one dir, main page]

UY39054A - Composición de liberación controlada - Google Patents

Composición de liberación controlada

Info

Publication number
UY39054A
UY39054A UY0001039054A UY39054A UY39054A UY 39054 A UY39054 A UY 39054A UY 0001039054 A UY0001039054 A UY 0001039054A UY 39054 A UY39054 A UY 39054A UY 39054 A UY39054 A UY 39054A
Authority
UY
Uruguay
Prior art keywords
controlled release
release composition
blood concentration
maintain
prevent
Prior art date
Application number
UY0001039054A
Other languages
English (en)
Inventor
Shoji Furuta
Hiroki Wakamori
Naoto Hattori
Chihiro Ishida
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of UY39054A publication Critical patent/UY39054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Es un objeto de la presente invención el de proporcionar una composición de liberación controlada que pueda prevenir un aumento repentino en la concentración en sangre de un ingrediente activo y pueda mantener la concentración en sangre durante un tiempo prolongado
UY0001039054A 2020-01-31 2021-01-29 Composición de liberación controlada UY39054A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020014880 2020-01-31

Publications (1)

Publication Number Publication Date
UY39054A true UY39054A (es) 2021-07-30

Family

ID=77079418

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039054A UY39054A (es) 2020-01-31 2021-01-29 Composición de liberación controlada

Country Status (4)

Country Link
AR (1) AR121207A1 (es)
TW (1) TW202140010A (es)
UY (1) UY39054A (es)
WO (1) WO2021153716A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291495B6 (cs) * 1992-09-18 2003-03-12 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017042731A1 (en) * 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
EP3335699A1 (en) * 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
EP3711763A4 (en) * 2017-11-16 2021-08-18 Nippon Shinyaku Co., Ltd. CONTROLLED RELEASE FORMULATION
WO2020157730A1 (en) * 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en) * 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
WO2020255157A1 (en) * 2019-06-20 2020-12-24 Aizant Drug Research Solutions Private Limited Stable solid dosage form of selexipag and process for preparation thereof

Also Published As

Publication number Publication date
WO2021153716A1 (en) 2021-08-05
TW202140010A (zh) 2021-11-01
AR121207A1 (es) 2022-04-27

Similar Documents

Publication Publication Date Title
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
CL2019000406A1 (es) Inhibidores de diacilglicerol aciltransferasa 2.
CY1121402T1 (el) Παρασιτοκτονες συνθεσεις οι οποιες περιλαμβανουν εναν δραστικο παραγοντα ισοξαζολινης, μεθοδοι και χρησεις αυτων
CR20190101A (es) Estimuladores de sgc
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
MX376829B (es) Dispositivo de fijacion que tiene una correa y vendaje integral.
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
MX2018012390A (es) Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
MX2016006025A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CO2018013925A2 (es) Almacenamiento anaeróbico de sangre y método de inactivación de patógenos
NI201400120A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY36033A (es) “inhibidores de diacilglicerol aciltransferasa 2”.
CL2020003074A1 (es) Inhibidores de la vía de respuesta al estrés integrada.
AR098586A1 (es) Sistema oxidante de dos partes para composiciones para el cuidado oral
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
CO2018012502A2 (es) Formulaciones y métodos para el tratamiento de organismos fotosintéticos y la mejora de las calidades y cantidades de rendimientos con formulaciones de compuestos de glicano
UY39054A (es) Composición de liberación controlada
EP4317173A4 (en) PEPTIDE AND COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
CL2024000716A1 (es) Compuestos contra parásitos en peces
CL2024000718A1 (es) Compuestos contra parásitos en peces
MX2018004381A (es) Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto.
PE20110283A1 (es) Composicion que contiene nifurtimox
EA201391085A1 (ru) Химическая композиция c пероксидом водорода и наноэмульсией длинноцепочечных спиртов
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento